Costochondritis and Tietze Syndrome (Investigational Adjunct)
Investigational adjunct for refractory costochondritis or Tietze syndrome; NSAIDs, reassurance, and physical therapy remain primary; cardiac and pulmonary causes must be excluded first.
Patienten-Zusammenfassung
- Ist dies FDA-zugelassen fuer diese Anwendung?
- Not FDA-cleared for costochondritis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for costochondritis or Tietze syndrome is investigational.
- Welche Evidenz existiert?
- Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based therapy for costochondritis: reassurance after cardiac and pulmonary causes are excluded, NSAIDs (oral or topical diclofenac), heat or cold application, and activity modification. Most cases resolve within 6-12 months. Tietze syndrome (with visible swelling) may benefit from corticosteroid injection. Cardiac chest pain must always be ruled out first.
- Hauptrisiken
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the anterior chest for 5 to 14 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Increased chest-wall pain after the procedure
- Risk of mistaking cardiac chest pain for costochondritis (delay in cardiac diagnosis)
- Permanent small scars at bite sites on the chest
- Delay of NSAID therapy or corticosteroid injection for Tietze syndrome
- Wer dies nicht in Betracht ziehen sollte
- Patients with chest pain that has not been cardiac-evaluated (ECG, possibly stress test or troponin)
- Patients with suspected pulmonary embolism, pneumothorax, or aortic dissection
- Patients with active myocardial infarction or unstable angina
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Pregnant patients
- Patients with rib fracture or chest-wall trauma in the past 6 weeks
- Was Sie Ihren Kliniker fragen sollten
- Have cardiac causes of my chest pain been adequately excluded?
- Have I been evaluated for pulmonary embolism if I have risk factors?
- Have I tried oral or topical NSAIDs for at least 2-4 weeks?
- If I have Tietze syndrome with visible swelling, am I a candidate for corticosteroid injection?
- What evidence specifically supports leech therapy for costochondritis?
- Are leeches from an FDA-registered supplier and used only once?
- What is the cost and is it covered by insurance? (typically not covered)
- Wann dringende medizinische Versorgung suchen
- Crushing or pressure-like chest pain with radiation to arm, jaw, or back (possible heart attack — call 911)
- Sudden severe shortness of breath or chest pain (possible pulmonary embolism or pneumothorax)
- Pain with sweating, nausea, or lightheadedness (possible cardiac event)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
Was dies NICHT bedeutet
- This is NOT FDA-cleared for costochondritis or Tietze syndrome.
- Anecdotal reports do NOT establish efficacy versus NSAIDs, heat, or corticosteroid injection.
- It does NOT replace cardiac evaluation — chest pain must always be cardiac-cleared first.
- It does NOT substitute for reassurance and time, which resolve most cases over 6-12 months.
- It does NOT distinguish musculoskeletal chest pain from serious cardiac or pulmonary disease.
Sicherheits-Querverweise
Clinical Profile
- Category
- musculoskeletal
- ICD-10
- M94.0
- Safety tier
- medium
Evidence Summary
Costochondritis is benign inflammation of the costochondral or costosternal junctions causing anterior chest wall pain; Tietze syndrome is the variant with localized swelling. Both are diagnoses of exclusion after cardiac, pulmonary, and gastrointestinal causes are ruled out. Standard management is NSAIDs, topical analgesics, reassurance, posture and breathing exercises, and occasional local corticosteroid injection. No controlled clinical trial of leech therapy for costochondritis or Tietze syndrome has been published; any use is investigational and mechanistic only. Application directly over the sternum or in the precordial area carries excess infection and bleeding risk and is contraindicated.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Wollina U (2008)0
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Cardiac or pulmonary cause of chest pain not yet excluded
- Direct sternal or precordial placement
- Recent thoracic surgery or fracture
- Known costal cartilage neoplasm
Related Conditions
Knee Osteoarthritis
Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.
Thumb Carpometacarpal (CMC-1) Osteoarthritis
Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.
Lateral Epicondylitis (Tennis Elbow)
Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.
Plantar Fasciitis
Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.